AACR-NCI-EORTC Virtual International Conference on **MOLECULAR TARGETS AND CANCER THERAPEUTICS** October 7-10, 2021




FINDING CURES TOGETHER*





CBX-12 (alphalex[™]-exatecan) sensitizes tumors to immune checkpoint blockade in an antigen agnostic manner by immune activation

Presenter: Sophia Gayle Cybrexa Therapeutics, New Haven CT





How We Do It: alphalex[™] Selectively Targets Tumor Cells








The future of cancer therapy

FINDING CURES TOGETHER



Platform has been validated by a number of institutions and investigators in academia and industry, with an extensive body of published preclinical data

AACR-NCI-EORTC VIRTUAL INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS


CBX-12: Selective Delivery of Exatecan to Tumors with Avoidance of Normal Tissue Tox







The future of cancer therapy




- Left: Activity of CBX-12 in GA2157 gastric PDX model after dosing 10 or 20 mg/kg QDx4/wk x 3 weeks. Study is ongoing.
- Right: Profile of white blood cell counts after 4 days of dosing the indicated dose of CBX-12 or an equimolar dose of unconjugated exatecan in nude mice

CBX-12 Synergizes with anti-PD1 in CT26 Colorectal Syngeneic Model





The future of cancer therapy



- Left: Activity of CBX-12 combination with anti-PD-1 in CT26 colorectal model after dosing 10 mg/kg CBX-12 QDx4/wk x 2 weeks and anti-PD1 Q4D x 4 as single agent and in combination.
- Right: Kaplan Meier survival analysis of combination study. The combination resulted in a significant survival benefit, with three animals undergoing a complete response.

CBX-12/anti-PD1 Combo Generates Long Term Anti-Tumor Immunity






NATIONAL CANCER INSTITUTE

B) A) 800-- Naive mice challenged with CT26 ★ Cured mice by CBX-12/Anti-PD1 rechallenged with CT26 700 Tumor Volume (mm³) Dav 5 DLN + No stimulation Day 5 DLN + CT26 stimulation 600 10mpk CBX-12 + 10mpk anti-mouse PD-1 (RMP1-14) 1000-1000-4000 **** 500 3500 **** 800-800 400 bg/ml FNY, pg/ml 600-600-2000 300 1500 IFN, 1000 400-400· * 200 ns 12 15 27 18 21 30 33 200-200 100 0 **CT26** Cured **CT26** Cured None None 20 30 0 40 Tumor Bearing 3/10 CR mice rechallenged Tumor Bearing on opposing flank

- A. The 3 CR mice from the CBX-12/PD1 combination arm (inset) were rechallenged with CT26 cells on the opposing flank (red). An additional 3 naive mice were injected with CT26 cells as a control (blue).
- B. 55 days after the rechallenge, draining lymph nodes from the 3 CR mice were isolated and single cell suspension incubated with inactivated CT26 cells in vitro. Draining lymph nodes from mice bearing CT26 tumors and no tumor were used as controls. IFNy production was measured after 5 days incubation.

CBX-12 Induces Immunogenic Cell Death to Confer Long Term Immunological Memory






A. Balb/c mice were vaccinated by cells killed *in vitro* by either freeze thawing or by CBX-12 treatment. Two weeks later, animals were injected on the same flank with a booster of freeze thawed or CBX-12 treated cells. 7 days post-vaccination, mice were reinjected with live CT26 cells on the opposing flank.
B. Spider plots of the study represented in (A). 9/10 mice in the CBX-12 arm remained tumor-free throughout the course of the experiment, while all animals in the control groups developed tumors.

AACR-NCI-EORTC VIRTUAL INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

Cytokine Biomarkers of Immunological Memory in CBX-12-Vaccinated Mice



NATIONAL CANCER INSTITUTE

The future of cancer therapy

for Cancer Research

INDING CURES TOGETHER


Naive: no vaccination + no CT26 challenge CT26: no vaccination + CT26 challenge-tumor bearing Protected: vaccination + CT26 rejection

- A. Induction of IL-2 in supernatant of splenocytes cultured ex vivo from naïve, CT26 tumor bearing, and CBX-12 vaccinated animals after 6 days of co-culture with inactivated CT26 cells.
- B. Induction of IFNy in supernatant of splenocytes cultured ex vivo from naïve, CT26 tumor bearing, and CBX-12 vaccinated animals after 5 days of co-culture with inactivated CT26 cells.


AACR-NCI-EORTC VIRTUAL INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

CBX-12 Synergizes with anti-CTLA4 in CT26 Colorectal Syngeneic Model





- Left: Spider plots of CBX-12 combination with anti-CTLA4 in CT26 colorectal model after dosing 10 mg/kg CBX-12 QDx4/wk x 2 weeks and 0.5 mg/kg anti-CTLA4 Q4D x 4 as single agent and in combination.
- Right: Kaplan Meier survival analysis of combination study.





- CBX-12 treatment results in tumor selective delivery of efficacious levels of exatecan while avoiding toxicity to normal tissues including immune components
- CBX-12 synergizes with anti-PD1 and anti-CTLA4
 - Responders display long term anti-tumor immunological memory in part due to the induction of immunogenic cell death by CBX-12
- Cybrexa aims to test immunotherapy combinations with CBX-12 clinically in 2022